NBY NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Receives Noncompliance Notice from NYSE MKT

EMERYVILLE, Calif.--(BUSINESS WIRE)--

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) today announced receipt of a letter from NYSE MKT LLC (“NYSE MKT” or the “Exchange”) on May 16, 2017, stating that it is not in compliance with the continued listing standards (requiring stockholders’ equity of $6.0 million or more if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years) as set forth in Section 1003(a)(iii) of the NYSE MKT Company Guide (“Company Guide”).

In order to maintain its listing, NovaBay Pharmaceuticals must submit a plan of compliance by June 15, 2017, addressing how it intends to regain compliance with Section 1003(a)(iii) of the Company Guide.

The Company intends to submit a plan to regain compliance with NYSE MKT listing standards. If the plan is not accepted, delisting proceedings will commence. If the plan is accepted, the Company’s common stock will continue to be listed on the NYSE MKT during the plan period. However, if the Company does not regain compliance with those standards or does not make progress consistent with the plan, the NYSE MKT staff may commence delisting proceedings.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Stay informed on NovaBay’s progress:

Download our Mobile InvestorApp from the Apple Store or Google Play

Like us on Facebook

Follow us on Twitter

Connect with NovaBay on LinkedIn

Join us on Google+

Visit NovaBay’s Website

NovaBay Contacts

For NovaBay Avenova purchasing information, please contact:

800-890-0329

www.Avenova.com

EN
19/05/2017

Underlying

NBYNovaBay Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NovaBay Pharmaceuticals

 PRESS RELEASE
Free
NBY NovaBay Pharmac...

NovaBay Pharmaceuticals’ Avenova® Warm Eye Compress for the Relief of ...

EMERYVILLE, Calif.--(BUSINESS WIRE)-- . (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces the availability of its new Warm Eye Compress on and on . This new, reusable heated eye compress is designed to relieve the symptoms associated with blepharitis, dry eye disease, meibomian gland disease, styes and chalazion, and is a companion product to Avenova, NovaBay’s premier antimicrobial lid and lash spray. This press release features multimedia. View the full release here: Avenova Warm Eye Compress (Graphic: Business Wire) “Most ...

March 31, 2021 1 EN
 PRESS RELEASE
Free
NBY NovaBay Pharmac...

Ra Medical Systems to Participate in Upcoming Virtual Investment Confe...

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will participate in two upcoming virtual investment conferences: 33rd Annual Roth Conference being held March 15-17, 2021. Ra Medical will hold virtual investor meetings. Investors interested in arranging a meeting should contact their Roth Capital Partners sales representative or LHA Investor Relations. Roth Conference information is available . Maxim 2021 Eme...

March 11, 2021 1 EN
 PRESS RELEASE
Free
NBY NovaBay Pharmac...

NovaBay CEO Issues Letter to Stockholders

EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay Pharmaceuticals (NYSE American: NBY) issued the following Letter to Stockholders: To My Fellow Stockholders: NovaBay Pharmaceuticals enters 2021 focused on growing sales of our high-quality, differentiated consumer products: ®, the premier antimicrobial lid and lash spray, and , a breakthrough product that marked our entry into a new beauty category late last year. I’m excited to announce that we will soon expand consumer access to both products to brick-and-mortar retail stores. Avenova will be available at CVS stores, one of the nation’s larges...

February 8, 2021 1 EN
 PRESS RELEASE
Free
NBY NovaBay Pharmac...

NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Plac...

NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain non-U.S. institutional accredited investors providing for the purchase and sale, in a private placement, of (i) the Company’s preferred stock automatically co...

August 9, 2019 1 EN
 PRESS RELEASE
Free
NBY NovaBay Pharmac...

NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered D...

NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,198,566 shares of common stock at a price of $1.00 per share in a registered direct offering, resulting in total gross proceeds of approximately $4.2 mill...

August 9, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch